| ￥9900 | |
| Z06551-100 | |
|
|
|
|
|
|
|
|
|
| Species | Human | ||||||
| Protein Construction |
|
||||||
| Purity | > 95% as determined by BisTris PAGE | ||||||
| Endotoxin Level | Less than 1EU per μg by the LAL method. | ||||||
| Biological Activity | Measured by its binding ability in a functional ELISA.Test result was comparable to standard batch. | ||||||
| Expression System | HEK293 | ||||||
| Theoretical Molecular Weight | 258 kDa | ||||||
| Apparent Molecular Weight | Due to glycosylation, the protein migrates to 260-265 kDa under Non reducing (N) condition based on Bis-Tris PAGE result. | ||||||
| Formulation | Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). | ||||||
| Reconstitution | Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. | ||||||
| Storage & Stability | Upon receiving, the product remains stable for 6 months at -20℃ or below. Upon reconstitution, the product should be stable for 3 months at -80℃. Avoid repeated freeze-thaw cycles. |
Immobilized HLA-A*02:01&B2M&AFP (FMNKFIYEI) Tetramer, His & Avi, Human, His Tag at 1 μg/ml (100 μl/well) on the plate. Dose response curve for Anti-HLA-A*02:01&B2M&AFP Antibody, hFc Tag with the EC50 of 4.1 ng/ml determined by ELISA. »
The purity of HLA-A*02:01&B2M&AFP (FMNKFIYEI) Tetramer, His & Avi, Human is greater than 95% as determined by SEC-HPLC. »
HLA-A*02:01&B2M&AFP (FMNKFIYEI) Tetramer, His & Avi, Human on Bis-Tris PAGE under Non reducing (N) condition. The purity is greater than 95%. »
Immobilized HLA-A*02:01&B2M&AFP (FMNKFIYEI) TCR at 2 μg/ml (100 μl/well) on the plate. Dose response curve for HLA-A*02:01&B2M&AFP (FMNKFIYEI) Tetramer, His & Avi, Human, His Tag with the EC50 of 26.6 ng/ml determined by ELISA. »
HLA-A*02:01&B2M&AFP (FMNKFIYEI) Tetramer, His & Avi, Human, His Tag captured on CM5 Chip via Anti-His Antibody can bind HLA-A*02:01&B2M&AFP (FMNKFIYEI) TCR with an affinity constant of 0.111 μM as determined in SPR assay (Biacore T200). »
| Target Background | Alpha-fetoprotein (AFP), a specific liver cancer marker, T cells expressing AFP-CAR selectively degranulated, released cytokines, and lysed liver cancer cells that were HLA-A*02:01 /AFP while sparing cells from multiple tissue types that were negative for either expressed proteins.CAR T-cell immunotherapy targeting intracellular/secreted solid tumor antigens can elicit a potent antitumor response. |
| Synonyms | Alpha-fetoprotein; Alpha-1-fetoprotein; Alpha-feto; AFP; HPAFP; AFPD; FETA; MHC |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
